Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
EGL Genetic Diagnostics, |
RCV000516943 | SCV000109780 | pathogenic | not provided | 2015-06-10 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000012055 | SCV000486281 | pathogenic | Adrenoleukodystrophy | 2016-07-12 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV000516943 | SCV000612228 | pathogenic | not provided | 2018-12-11 | criteria provided, single submitter | clinical testing | The variant results in a shift of the reading frame, and is therefore predicted to result in the loss of a functional protein. Found in at least one symptomatic patient, and not found in general population data. |
Gene |
RCV000516943 | SCV000617388 | pathogenic | not provided | 2017-05-30 | criteria provided, single submitter | clinical testing | The c.1415_1416delAG pathogenic variant in the ABCD1 gene has been previously reported in multiple unrelated individuals as a common variant associated with varying forms of X-linked adrenoleukodystrophy (Kemp et al., 2004; Feigenbaum et al., 1996; Kemp et al., 2001). This variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The c.1415_1416delAG variant causes a frameshift starting with codon Glutamine 472, changes this amino acid to a Arginine residue, and creates a premature Stop codon at position 83 of the new reading frame, denoted p.Gln472ArgfsX83. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Therefore, we interpret c.1415_1416delAG as a pathogenic variant. |
Invitae | RCV000012055 | SCV000629988 | pathogenic | Adrenoleukodystrophy | 2019-08-12 | criteria provided, single submitter | clinical testing | This sequence change deletes 2 nucleotides from exon 5 of the ABCD1 mRNA (c.1415_1416delAG), causing a frameshift at codon 472. This creates a premature translational stop signal (p.Gln472Argfs*83) and is expected to result in an absent or disrupted protein product. Loss-of-function variants in ABCD1 are known to be pathogenic. This particular variant has been reported in the literature in several individuals affected with childhood or adult-onset adrenoleukodystrophy or adrenomyeloneuropathy (PMID: 8048932, 23154058, 23768953, 23566833, 22479560, 7849723). This variant is also referred to as 1801delAG in the literature. ClinVar contains an entry for this variant (Variation ID: 11303). For these reasons, this variant has been classified as Pathogenic. |
ARUP Laboratories, |
RCV000516943 | SCV000883323 | pathogenic | not provided | 2017-11-09 | criteria provided, single submitter | clinical testing | |
Integrated Genetics/Laboratory Corporation of America | RCV000012055 | SCV001338292 | pathogenic | Adrenoleukodystrophy | 2020-02-10 | criteria provided, single submitter | clinical testing | Variant summary: ABCD1 c.1415_1416delAG (p.Gln472ArgfsX83) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 182139 control chromosomes. c.1415_1416delAG has been extensively reported in the literature in multiple individuals from diverse ethnic cohorts affected with Adrenoleukodystrophy. Some of the original reports of its identification are ascertained here (example, Feigenbaum_1996, Kemp_1994, Kok_1995, Ligtenberg_1995, Coll_2005, Pan_2005). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in a complete absence of protein expression (example, Feigenbaum_1996, Coll_2005). Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Institute of Human Genetics, |
RCV000012055 | SCV001429086 | pathogenic | Adrenoleukodystrophy | 2018-06-19 | criteria provided, single submitter | clinical testing | This variant was identified as hemizygous |
Foundation for Research in Genetics and Endocrinology, |
RCV000012055 | SCV001429638 | pathogenic | Adrenoleukodystrophy | 2020-07-20 | criteria provided, single submitter | clinical testing | A hemizygous 2 base pair deletion in exon 5 of the ABCD1 gene that results in a frameshift and premature truncation of the protein 83 amino acids downstream to codon 472 was detected. The observed variant c.1415_1416delAG (p.Gln472ArgfsTer83) has been reported previously in patients affected with adrenoleukodystrophy (Niu et al. 2013) and also classified as pathogenic in the ClinVar database. The variant has not been reported in the 1000 genomes and gnomAD databases. The reference region is conserved across mammals. In summary, the variant meets our criteria to be classified as pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV000516943 | SCV001448165 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000012055 | SCV000032289 | pathogenic | Adrenoleukodystrophy | 1994-10-01 | no assertion criteria provided | literature only | |
Gene |
RCV000012055 | SCV001156246 | pathogenic | Adrenoleukodystrophy | 2018-02-15 | no assertion criteria provided | literature only |